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Abstract

Defining the autoantigenic targets of T cells involved in insulindependent diabetes mellitus (IDDM) is essential for understanding the
pathogenesis of diabetes. IDDM results from the autoimmune destruction of
the pancreatic islet (3 cells. The non-obese-diabetic (NOD) mouse is a murine
model for spontaneous IDDM. T cells play an important role in the
pathogenesis of diabetes, and CD8 T lymphocytes may be critical initiators of
diabetes. Several [3-cell specific autoantigens of CD4 T cells have been
identified. However, the autoantigens of CD8 T cells, which are likely to play
an important role in the induction of diabetes, have not yet been identified.
In this thesis we describe the application of a single-cell T cell assay, which
takes advantage of a lacZ reporter construct, as a means to identify the target
antigen of a diabetogenic CD8 T cell clone isolated from young NOD mice.
Indicator cells are lacZ -inducible T-cell hybrids specific for the unknown
antigen, and are shown here to turn blue in the presence of NOD mouse islets
and the chromogenic substrate X-gal. These T cell hybrids, and COS-7 cells
transfected with the murine

MHC class I molecule as antigen-presenting

cells, have been used to screen a NOD mouse islet cDNA library for the target
antigen of the diabetogenic CD8 T cell clone. Our findings suggest that
increasing the sensitivity and specificity of the lacZ assay may be necessary for
detecting autoantigenic cDNA when it exists at very low frequencies in the
cDNA library.
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Introduction

Overview
Identifying the antigens on (3 cells targeted in type 1 diabetes is key to
understanding the pathogenesis of this autoimmune disease, and promises to
be useful for early diagnosis, and specific modulation of the immune process.
Many researchers have searched for the antigen responsible for inducing
diabetes in non-obese diabetic (NOD) mice. Their results have been enticing,
yet remain controversial, and the existence of a dominant disease-initiating
antigen has not been identified. Most of the candidate antigens proposed thus
far are recognized by CD4 T cells, and not CD8 T cells, which may be the
critical initiators of diabetes. Here we present the application of a recently
introduced method that sensitively measures T-cell activation, and a strategy
for identifying class I-restricted T cell antigens (Karttunen et al., 1992), as a
means to elucidate the target antigen of cloned CD8 T cells (Wong et al., 1996)
which were obtained at an early stage of disease in the NOD mouse, and
which cause rapid-onset diabetes in the absence of CD4 T cells.

1. T cell maturation: MHC restriction and self tolerance
A critical function of T cells is to distinguish healthy tissue from
infected tissue. They do so by recognizing foreign or altered proteins on the
surface of cells in the context of MHC molecules. There are two classes of
MHC molecules which differ in the source of the peptides they bind and carry
to the cell surface. MHC class I molecules bind fragments of endogenous
peptides, such as self antigens and fragments of viral proteins, generated in
the cytosol and then transported to the endoplasmic reticulum (Figure 1)
(Germain and Margulies, 1993). Extracellular antigenic proteins such as from
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most bacteria are made visible to the immune system via the MHC class II
presentation pathway. Class II molecules sample the contents of intracellular
vesicles, and thus display peptide fragments which have been internalized by
phagocytic cells which include macrophages, B cells, and specialized antigen
processing cells (APCs) called dendritic cells (Figure 1) (Germain and
Margulies, 1993).
T cell precursors arise in the bone marrow and travel to the thymus
(Ikuta et al., 1992). Here, gene rearrangements results in the assembly and
expression of unique, exclusively membrane-bound T cell receptors (TCRs)
(Matis, 1990). Subsequently, T cell maturation occurs and comprises two
selective processes known as positive selection and negative selection.
Positive selection ensures that T cells recognize self MHC molecules.
All T cell receptors recognize MHC genes of the species, and virtually all of
them recognize antigen in the form of peptide:MHC complexes. The ability of
T cells to recognize specific antigens only in the context of self MHC
molecules is also called MHC restriction. In order to receive important
developmental signals from the thymic microenvironment, T cells must still
possess an affinity for self-MHC molecules. Furthermore, MHC restriction
ensures that T cells can potentially bind these molecules when they contain
foreign antigenic peptides (Hogquist et al., 1994). Through a process that is
not well understood T cells that recognize peptides in the context of MHC
class I molecules (class-I-restricted) mature into cytotoxic T cells, expressing
the CD8 co-receptor, whereas thymocytes that recognized peptides in the
context of MHC class II molecules (class-II-restricted) generally mature into
helper CD4 T cells (Kaye et al., 1989; Kisielow et al., 1988; Sha et al., 1988). CD4
T cells differentiate into two functional types depending on their cytokine
profiles: Thl cells and Th2 cells. Cells that do not encounter their restricting
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Exogenous

Figure 1. Schematic representation of the MHC class I and class II antigen
processing pathways. Endogenous synthesis of protein antigens results in the
production of peptide-MHC class I complexes. Peptide- MHC class 13
complexes are generated only in cells that express MHC class II molecules,
such as professional APCs, via endocytosed native proteins or phagocytosed
bacteria. [Figure adapted from Kuby, J. (1997) Immunology 3rd ed (W.H.
Freeman and Company. New York, New York) p. 257]
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MHC molecule in the thymus die before attaining functional maturity (Surh
and Sprent, 1994).
Negative selection ensures that T cells are not reactive to MHC-peptide
ligands found on self tissue, and are thus self-tolerant (von Boehmer et al.,
1993). Many thymocytes that are positively selected in the thymus possess
receptors which are reactive to self peptides (Pullen et al., 1988; Sha et al.,
1988). These self-reactive thymocytes are eliminated either through
programmed cell death in the thymus, also called clonal deletion, or remain
functionally inactive in the periphery (Miller and Morahan, 1992).
Only the thymocytes whose TCRs have met the two selection criteria:
self-tolerance and self-restriction, develop into mature thymocytes (Sha et al.,
1988). This functions as a stringent screen mechanism upon developing
thymocytes. In fact it is estimated that during negative and positive selection
the vast majority of thymocytes, estimated around 98%, never leave the
thymus but undergo apoptosis (Strasser, 1995; Surh and Sprent, 1994).

2. Co-stimulatory molecules and peripheral T cell tolerance
T cell activation is a complex process that requires at least two
simultaneous signals from the same professional APC. The first is delivered
through the T cell receptor (TCR), and involves recognition of a peptide
fragment of antigen presented in the context of MHC molecules on the
surface of an APC. The second signal, referred to as co-stimulation, is
mediated through the binding of CD28 on T cells to co-stimulatory molecules
on the same APC. Costimulation is required for optimal activation of naive
T cells (Liu and Janeway, 1992). In fact, rather than activation, engagement of
the TCR complex of naive T cells in the absence of co-stimulation leads to T
cell anergy (Gimmi et al., 1993; Schwartz, 1990) or cell death (Liu and Janeway,
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1992). It is thought that the requirement of two signals by one cell represents
a mechanism for maintaining self-tolerance. Self tolerance would be lost if T
cells recognizing self-antigens on the surface of tissue cells could be co¬
stimulated by resident or distant APCs, and not by the cell bearing the specific
antigen (Schwartz, 1989).
The best characterized costimulatory molecule, B7-1, interacts with
receptors on the surface of T cells. These include CD28 and CTLA-4, a receptor
which is expressed only once T cells are activated and for which B7-1 has a
very high affinity to (Freeman et al., 1991; Linsley et al., 1991). B7-CD28
interaction has been clearly shown to activate CD4 T cells, and leads to the
production of cytokines such as IL-2 and IFN-y (Freeman et al., 1991; Gimmi et
al., 1993; Linsley et al., 1991). The role of the costimulatory pathway for CD8 T
cells is less clear, although it has been demonstrated that these cells can also
be activated following B7-1 interaction (Tan et al., 1992). However, it seems
that B7-1 interaction may stimulate T cell activation and not effector function
(Harding and Allison, 1993).

3. Autoimmunity: loss of self-tolerance
Autoimmune disease occurs when a specific adaptive immune
response is mounted against self antigens, or when self-tolerance is lost.
Since negative selection, and peripheral inactivation by the absence of co¬
stimulation, are both very efficient processes it is unlikely that autoimmunity
results from the failure of these two major mechanism of self tolerance
(Janeway and Travers, 1997). Antigens that are expressed abundantly in the
periphery induce clonal deletion or anergy. On the other hand, very rare
antigens that are presented poorly on tissue cells are unable to activate
antigen-specific T cells, which are present in the individual. These cells are

6

not normally activated, and are said to be immunologically ignorant. They
require special circumstances to be activated and are likely responsible for
most autoimmunity.

Antigens which are presented at intermediate levels on

tissue cells, such as those selectively expressed in the thyroid or the pancreatic
islets, usually do not activate immunologically ignorant T cells, since the
antigen would not be presented along with a co-stimulatory molecule.
However, if the T cell was inappropriately activated, it would then go on to
attack such tissues (Janeway and Travers, 1997; Katz et al., 1993).
Another theory of the mechanisms underlying the loss of self¬
tolerance involves a change in the balanced state between aggressive and
protective immune mechanisms.

In both the human disease and the NOD

mouse model, diabetes is preceded by a long phase of islet-cell-specific
autoreactivity, before hyperglycemia is manifested, and this silent phase is
thought to correspond to the active suppression of autoreactive T cells by
regulatory, or suppressor T cells, in the periphery. In NOD mice, transfer of
certain islet-specific T cell clones can prevent the destruction of pancreatic
islet cells (Reich et ah, 1989). Likewise, during the early phase of insulitis
mice are resistant to the transfer of disease by diabetogenic T cells (Bendelac et
al., 1987), and this resistance can be broken down by selectively depleting CD4
T cells (Sempe et al., 1994). It is unclear what triggers the breakdown from
active tolerance to overt diabetes. However, it is thought that self-tolerance to
pancreatic |3 cells is maintained by CD4 regulatory Th2 T cells, that produce IL4 and IL-10, and provide help for the activation of B cell-mediated humoral
responses. Th2 regulatory cells seem to suppress the activation of CD4
autoreative Thl cells, that produce INF-y, and IL-2, and tend to activate
macrophages and cytotoxic CD8 T cells (Cameron et al., 1998; Pilstrom et al.,
1995; Rabinovitch et al., 1995). There is evidence that when diabetes occurs

7
there is a shift to a Thl profile (Shimada et al., 1996), and that protection can
be brought out from a shift from a Thl to a Th2 type of response (Cameron et
al., 1997; Mueller et al., 1996). However, it is likely that a number of immune
defects in addition to a Thl/Th2 imbalance contribute to the development of
diabetes in the NOD mouse. Furthermore, the relevance of such deficiencies
in NOD mice has yet to be correlated to human disease.

4 The NOD mouse
Overview
Type 1 diabetes results from the interplay of genetic, environmental,
and autoimmune factors, and leads to the selective destruction of insulinproducing pancreatic (3 cells. NOD mouse diabetes develops spontaneously,
and possesses striking similarities to human type 1 diabetes. As such, the
NOD mouse has become the most widely studied model of human diabetes.
NOD mouse diabetes is not completely identical to human diabetes. For
instance, there is no gender predominance in human diabetes whereas in
NOD mice there is. In addition, high levels of islet-reactive autoantibodies
exist in humans, whereas only low levels are found in NOD mice.
Nevertheless, the NOD mouse model may serve to uncover the pathogenesis
of diabetes, and allows for insight into the development of autoimmune
diabetes in humans.
The NOD mouse was described as a diabetes model in Japan in the late
1970s (Makino et al., 1980). The mice develop an inflammatory infiltrate,
called "insulitis", within the pancreatic islets at about 3-4 weeks of age, or the
time of weaning. Dendritic cells and macrophages perhaps infiltrate first
(Jansen et al., 1994), followed by T cells (both CD4 and CD8) and B cells (Kay et
al., 1991; O'Reilly et al., 1994). Diabetes begins to occur at about 12 weeks of

'
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age, correlating with islet (3 cell destruction, and hyperglycemia (Bach, 1994).
In addition, the appearance of autoantibodies (Bottazzo et al., 1989; Castano
and Eisenbarth, 1990), defects in T cell activity (Serreze and Leiter, 1994), the
sensitivity of the disease to immunosuppression (Bottazzo et al., 1989), and
the presence of predisposing major histocompatibitiy complex (MHC) genes
(Wicker et al., 1995) all suggest an autoimmune basis for the disease.

A.

Idd genes and MHC class II molecules
IDDM in the NOD mouse is controlled by multiple susceptibility (Idd)

genes both within and outside the MHC (Serreze and Leiter, 1994). As many
as 15 loci critical to the IDDM process have been detected by genetic studies
(Todd et al., 1991), though only a very few have been identified.
The most important genetic component leading to IDDM susceptibility
in NOD mice is the strain's MHC genes (Vyse and Todd, 1996). The MHC
class II region, formerly Iddl, has been identified as a necessary but not
sufficient predisposing genetic factor for diabetes (Tisch and McDevitt, 1996).
The NOD mouse MHC class II molecule, I-A87, the homologue to human
leukocyte antigen (HLA) DQ molecules, is composed of an I-Aad chain plus a
unique I-A(3g7 chain that contains histidine-serine residues at amino acid
positions 56 and 57, rather than the usual proline-aspartic acid residues seen
in most other strains (Acha-Orbea and McDevitt, 1987). Diabetes can be
prevented when I-Ag7 is altered by substitution at position 56 (Lund et al.,
1990). The I-Ag7 motif is remarkably similar to HLA DQ8, in that linkage
between the lack of aspartic acid at the 57 position of the (3 chain and
susceptibility to diabetes is also found with human DQ molecules (Kwok et
al., 1996; Todd et al., 1988).
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The nature of the binding properties of the I-Ag7 allele has been
studied, but remains controversial. Work by Cohen and colleagues suggests
that the peptide-binding motif of TA8? is similar to that of HLA DQ (Reizis et
al., 1997; Reizis et al., 1997). Their findings suggest that the I-A8? molecule
binds peptide adequately, and that it induces good T cell responses. Harrison
et al (Harrison et al., 1997) propose a different I-A8? peptide-binding motif,
though they also find that the I-A8? molecule is a good peptide-binder. On the
other hand, others have found that I-Ag7 molecules are unstable, and are poor
peptide binders (Carrasco-Marin et al., 1997). This has led to the hypothesis
that, since elimination of autoreactive T cells requires a threshold period of
time in contact with peptide-MHC complexes (Ashton-Rickardt and
Tonegawa, 1994), T cells in contact with unstable complexes would tend to
escape negative selection in the thymus. In fact, studies have found that mice
carrying the H-28? class II molecules contained about 8-fold more autoreactive
T cells, than their congenic counterparts bearing H-2 MHC (Kanagawa et al.,
1998). This issue remains to be resolved and has important implications not
only for T cell selection but T cell reactivity in response to antigen
presentation. The diabetogenicity of the NOD mouse H2g7 MHC haplotype is
further enhanced by the lack of I-E expression on NOD APC's, due to a
mutation in the first exon of the Ea gene (Ikegami et al., 1990). IDDM is
inhibited in the NOD mouse with expression of the I-E transgene derived
from diabetes resistant MHC haplotypes (Lund et al., 1990; Nishimoto et al.,
1987).

B.

MHC Class I molecules
Though the role of MHC class I region has been studied less than that

of class II, it is clear that common class I alleles, such as Kd or Db, encoded by

*
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the H2g7 MHC haplotype of NOD mice play an essential role in the
development of IDDM. As it will be described later, the requirement of MHC
class I expression was demonstrated following the development of (32microglobulin knock-out ((32m”u//) NOD mice which do not express H-2S7 class
I molecules, and remain free of diabetes (Serreze et al., 1994). IDDM is also
inhibited in NOD mice that are congenic for the MHC haplotype of the CTS
mouse strain, that shares the same MHC class II allele, but not the class I
allele, of the NOD mouse (Ikegami et al., 1995). Similarly, it has been recently
demonstrated that certain MHC class I alleles such as HLA-A2 in humans
may play a role in enhancing IDDM susceptibility (Demaine et al., 1995;
Fennessy et al., 1994).

5. The diabetogenic roles of CD4 and CD8 T cells
Overview
Diabetes is an ancient disease and is quite prevalent, yet facets of this
disease are poorly understood, including the immunological mechanisms
which initiate it. It has been established that IDDM results from a T-cell
dependent autoimmune process directed against the pancreatic (3 cells,
however the role of these particular T lymphocyte subsets, and their target
antigens, remains to be elucidated.
T cells are important in the pathogenesis of diabetes. Histological
analysis of islet lesions reveal the presence of both CD4 and CD8 T cells
(Miyazaki et al., 1985). Injection of anti-CD3 antibodies inhibits disease
progression (Hayward and Shreiber, 1989). However, the precise contribution
of CD4 and CD8 T cells to disease progression is uncertain. Several groups
have shown that both CD4+ and CD8+ T cells from young diabetic donors are
required for disease transfer into neonatal, irradiated young, or genetically T
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cell-deficient NOD recipients (Bendelac et al., 1987; Christianson et al., 1993;
Miller et al., 1988; Rohane et al., 1995) indicating that these cells likely have
synergistic roles. CD4 T cells alone invade the islets, but diabetes develops
only in the presence of CD8 T cells. CD8 cells, alone, cannot transfer insulitis
or diabetes (Christianson et al., 1993; Thivolet et al., 1991). These findings led
to the notion that CD4 T cells may initiate diabetes, and recruit CD8 T cells,
the effector cells capable of carrying out the final destruction of islet p cells.
This idea was consistent with other data, such as the isolation of CD8 T cell
clones with in vitro and in vivo anti-islet beta cell cytotoxic activity [Reich et
al, 1989 #40; Nagata, 1989 #474; Hayakawa, 1991 #290; Nagata, 1994 #239;
Nagata, 1992 #242]. Some studies found that CD4 cells precede the entry of
CD8 T cells into islets, following the transfer of whole splenocytes from
diabetic donors into to healthy recipients (O'Reilly et al., 1991). On the other
hand, others have shown that macrophages and CD8 T cells are the earliest
infiltrating cells. (Bedossa et al., 1989; Jarpe et al., 1990).

A.

CD8 T cells as initiators of diabetes
More recently, there is an increasing body of evidence that CD8 T cells

are important in the initiation of diabetes in addition to playing a cytotoxic
role in the final stages of P cell destruction. Pancreatic P cells are generally not
regarded as effective APC's, possessing MHC class I molecules, but not class II
molecules on their surface (Mclnerney et al., 1991; Signore et al., 1989).
Therefore, if CD4 T cells are to recognize P cell antigens, they must do so in
the context of I-A87 molecules on the surface of professional antigenpresenting cells (APC's), such as macrophages and dendritic cells residing in
the pancreatic islets. As such, it seems likely that an initial P cell insult
occurs, mediated by MHC class I-restricted CD8 T cells, followed by the release

'
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of soluble antigens that are then processed and presented by APCs to CD4 T
cells. An initiating function of CD8 cells would also be more in line with
human diabetes, where CD8 T cells seem to dominate the islet infiltrate of in
newly diagnosed patients (Bottazzo et al., 1985; Hanninen et al., 1992; Itoh et
al., 1993) and are highly activated in the blood (Hehmke et al., 1995).

B.

MHC Class I molecules and the role of CD8 T cells
The strongest evidence that CD8 T cells may be important in the

initiation of type 1 diabetes comes from studies in which NOD mice are bred
to lack functional MHC class I molecules and consequently most CD8 T cells.
MHC class I molecules consist of a 45 kD polypeptide chain, the alpha chain,
which is non-covalently associated at the cell surface with [32-microglobulin
(|32-m). In 1990 it was reported by two groups that following the disruption of
the [32-m gene by targeted mutation, mice are unable to express |32-m, and
therefore MHC class I molecules (Koller et al., 1990; Zijlstra et al., 1990).
However, MHC class II expression and CD4 cells appears normal.
Consequently, these mice lack virtually all mature CD8 T cells, supporting
previous evidence that interactions with class I MHC molecules are essential
for CD8 T cell development (Sha et al., 1988; Zuniga-Pflucker et al., 1989).
As a means to further examine the relative contributions of MHC class
I-restricted and MHC class II-restricted T cells to autoimmune pancreatic (3 cell
destruction, several groups bred NOD mice with (32-m knock-out mice (NOD$2mnull) (j^atz et al., 1993; Serreze et al., 1994; Sumida et al., 1994; Wicker et al.,
1994). It was found that NOD mice deficient in MHC class I expression and
CD8 T cells, remained completely free of both insulitis and diabetes. These
results seem to argue that CD8 T cells are crucial for the initiation of diabetes
in NOD mice. Further evidence of the initiating role of CD8 T cells in

N
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diabetes came from studies demonstrating the inhibition of insulitis
following the injection of anti-CD8 monoclonal antibodies into young NOD
mice, between 2 and 5 weeks of age (Wang et al., 1996). These results also
suggest that it is the lack of CD8 T cells, rather than the lack of MHC class I
molecules, which prevents infiltration of the islets.

Finally, supporting

evidence for the participation of CD8 T cells in disease initiation has come
from studies demonstrating that T cells from young prediabetic NOD mice
transfer disease to MHC class I-positive NOD-SCID mice but not to NOD-SCID
mice bearing the (32mnw^ mutation (Serreze et al., 1997). It is also evident that
the absence of CD4 T cells, such as with NOD.CD4-/- mice (Wong et al., 1998),
and following anti-CD4 antibody treatment (Shizuru et al., 1988), prevents
insulitis and diabetes. Thus, there is a dual role played by CD4 T cells and CD8
T cells in disease initiation.
It is important to recognize that the critical role of CD8 T cells in
initiation of diabetes does not exclude their effector function. The transfer of
diabetes to NOD-(32mnu^ recipients with diabetic spleen cells is considerably
delayed compared with wild-type NOD mice (Kay et al., 1996; Wicker et al.,
1994). It is possible that once activated, the CD4 cells in this transfer
population are able to target and destroy $2mnul1 islet (3 cells. This suggests a
role for substantial numbers of CD8 T cells in the effector phase of diabetes.
Likewise, when NOD(32mnu^ mice are made transgenic for (32m on the rat
insulin promoter (RIP), thus restoring MHC class I expression only on islet |3
cells, mice rapidly developed diabetes, following the transfer of diabetic spleen
cells, at the same rate as wild-type NOD recipients (Kay et al., 1996).
Interestingly, restoration of P-cell MHC class I, without restoring CD8 T cells,
was sufficient to cause insulitis but not diabetes. This might be explained by
previous findings that (32m”w^ mice possess small numbers of CD8 T cells
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which are probably not functional in the absence of MHC class I expression
(Lehmann-Grube et al., 1994; Zijlstra et al., 1992). In RIP-P2m/NOD(32mnw//
mice this small population may be able to initiate damage of P cells, yet
remain too scarce to be involved in the final effector stage of diabetes.

C.

T cell effector mechanisms
As previously discussed, CD4 and CD8 T cells play a role in both the

initiation and the effector phase of P-cell destruction. It is not clear however,
if the requirement for both CD4 and CD8 T cells in diabetes results from their
synergistic or independent contributions.

Furthermore, the mechanisms by

which P cell destruction by CD4 and CD8 T cells occurs is not well established.
It seems that CD8 T cell cytotoxicity results from the direct production of the
effector molecule perforin, and granzymes. These molecules are also able to
induce programmed cell death, or apoptosis. Apoptosis is also mediated by
membrane-associated TNF-related molecules, such as Fas ligand, which
interacts with Fas, its receptor, on target cells. Support for perforin-mediated
P cell destruction comes from the LCMV-gp model. These mice are made
perforin-deficient, and when LCMV-gp-specific T cells are activated following
LCMV viral infection, they do not develop diabetes (Kagi et al., 1996), and
perforin-deficient NOD mice have delayed onset of diabetes (Kagi et al., 1997).
On the other hand, recent evidence indicates that apoptosis, as a result of
Fas/Fas ligand interactions, in the NOD mouse may represent a dominant
mode of islet P cell destruction by CD8 T cells (Chervonsky et al., 1997).
Additionally, CD4 T cells have also been shown to destroy P cells. Since P
cells do not express MHC class II molecules it is generally thought that CD4 T
cell destruction is mediated indirectly, following their activation by APCs
bearing P-cell-specific antigens. Alternatively, CD4 T cells could kill P cells by
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inducing apoptosis. Kurrer et al (1997), using a TCR from the CD4 T cell clone
BDC2.5, have shown that [3 cells die by apoptosis following interactions with
BDC2.5 cells, and that death is triggered by a mechanism other than Fas/FasL,
such as TNFa-TNFR interactions. Islet cells do not normally express Fas, but
can be induced to up-regulate its levels by IL-1 and interferon-y (IFN-y) (Stassi
et al., 1996; Yamada et al., 1996). Thus, cytokine production by CD4 and CD8 T
cells may up-regulate Fas on islets, at which point Fas ligand-expressing CD8
T cells and CD4 cells would induce apoptosis (Wong and Janeway, 1997).
In earlier studies with NOD mice, investigators in our laboratory
generated NOD mice that express the B7-1 co-stimulatory molecule, using the
rat insulin promoter-1 (RIP), on pancreatic (3 cells. At the first backcross to
NOD, mice homologous to the NOD MHC develop accelerated diabetes, with
more than half the animals developing diabetes before 12 weeks of age.
Under normal circumstances (3 cells do not express costimulatory molecules
(Stephens and Kay, 1995). In this NOD-R1P-B7-1 model, it appears as though
B7-1 expression allows (3 cells to be effective APC's. They become potent
stimulators of CD8 T cells that are specific for |3 cell antigens presented by
MHC class I molecules. Interestingly, both CD4 and CD8 T cells are required
for the acceleration of diabetes in this model (Susan Wong et al., 1998).
It remains a possibility that T-cell activation in NOD mice does not
require costimulation with B7 and could result from the interaction of CD8 T
cells with B7-negative (3 cells. It is hypothesized that CD8 T cells are activated
outside the pancreas in surrounding lymph tissue, where they recognize their
antigen in the context of a costimulatory signal on the surface of APC's.
These activated cells could then recognize their antigen within islets without
the need of direct costimulation by B7 molecules (Wong and Janeway, 1997).
There is increasing evidence that B lymphocytes may play a critical role in the
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induction of diabetes, since their depletion causes resistance to both diabetes
and insulitis (Noorchashm et al., 1997; Serreze et al., 1996). This effect likely
relates to the ability of B cells to present antigen and costimulate T cells. On
the other hand, it has recently been shown that dendritic cells, but not
macrophages, efficiently present antigens derived from apoptotic cells which
can then stimulate MHC class-I-restricted cytotoxic CD8 T cells (Albert et al.,
1998). This may represent an exogenous pathway for CD8 T cell activation
against target islet (3 cell antigens.

D.

Diabetogenic CD4 and CD8 T cell lines and clones
With the advent of cloned T cell lines, it seemed that information on

the relative contributions of CD4 and CD8 T cells to (3 cell destruction, as well
as interactions between the two populations might be further delineated.
However, the diabetogenicity of various lines and clones is apparently quite
variable (Table 1). In addition, the requirement for both T cell subsets to cause
diabetes is not as clear when T cell clones are used. In some reports, CD4 T
cell clones can transfer disease but require the presence of CD8 T cells (Nagata
et al., 1994; Pankewycz et al., 1991; Reich et al., 1989; Shimizu et al., 1993). On
the other hand, several groups have isolated CD4 T cell clones (Daniel and
Wegmann, 1996, Zekzer, 1997 #485; Peterson and Haskins, 1996) reactive to
islets or known islet antigens, which can transfer diabetes in 4-7 weeks in the
absence of other cells.
CD8 T cell clones are difficult to isolate, and consequently there are
fewer reports of islet-specific CD8 T cell clones than there are CD4 clones. In
addition, investigators have generally not observed disease transfer when
CD8 clones are used alone, but only when they are cotransferred with CD4
lines or spleen cells (Nagata et al., 1994; Santamaria et al., 1995; Verdaguer et
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al., 1996). Other researchers (Shimizu et al., 1993) isolated CD8 T cell clones
from pancreatic islets of NOD mice which did not transfer disease even in the
presence of CD4 T cells. However, investigators in our laboratory have
recently generated an islet-specific CD8 T cell clone which has the capacity to
cause diabetes rapidly (within 10 days) when transferred to irradiated NOD,
young NOD-SCID, and CB-17-SCID mice, in the absence of CD4 cells (Wong et
al., 1996).
These diabetogenic CD8 T cell clones were isolated from the pancreatic
islets of young 7 week old NOD mice, which have insulitis but are not yet
diabetic. They differ from other CD8 T cell clones in that they were grown on
islets from B7-1 -expressing (NOD X C57BL/6J-RIP B7-1)F1 hybrid mouse cells
are highly cytotoxic, and express IFN-y, TNF-a, TNF-J3, and the effector
molecule perforin. They rapidly destroy pancreatic islets in recipient NOD
mice that do express B7-1 in their pancreases, indicating that B7-1 is not
required for specific recognition or final effector function (Wong et al., 1996).
It has previously been demonstrated that T cells, capable of targeting
and damaging islets, are present in the islets of young, pre-diabetic NOD mice
(Rohane et al., 1995). It is important to note that these cells are highly
cytotoxic, and express IFN-y, TNF-a, TNF-(3, and the effector molecule
perforin. They rapidly destroy pancreatic islets in recipient NOD mice that do
express B7-1 in their pancreases, indicating that B7-1 is not required for
specific recognition or final effector function (Wong et al., 1996). It is
important to note that the CD8 T cell clone isolated by Wong and colleagues
(1996) was isolated from 7 week-old mice that had insulitis but would not be
diabetic for several weeks. Therefore, these cells may represent a population
of cells capable of inflicting significant damage to islets, and may be
contributing to the initiation of the autoimmune process.

,
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6. Autoantigens in type 1 Diabetes
Studies of NOD mouse from the neonatal period through to diabetes
onset has led to view that the diabetogenic process is a step-wise development
marked by two proposed 'checkpoints' (Andre et al., 1996). The first is seen at
about 4-6 weeks of age, and is characterized by peri-insulitis. Following this,
there is direct invasion of the islets by infiltrating cells, or intra-insulitis,
which is dependent on recognition of P cell antigens (Wicker et al., 1992). A
temporal analysis of P cell reactivity suggests that a few autoantigens are
targeted early in insulitis (Kaufman et al., 1993; Tisch et al., 1993), and that
intra-insulitis results in the recruitment of additional P-cell reactive T cells in
the periphery. The onset of diabetes at 18-20 weeks represents the second
checkpoint, and does not seem to be driven by insulitis per se (Katz et al.,
1993). These events may depend on changes in regulatory and effector T cells,
or possibly a cascade of antigen recognition, or both.
It has been about a decade since the identity of most known p cell
autoantigens were determined. Despite this progress, many questions
remained unanswered, particularly the intriguing question of whether a
dominant, initiating antigen exists, and what is its nature. The roles of
known P cell antigens are poorly understood, including whether they are in
fact pathogenic. Particular P cell antigens in IDDM have been studied by first
correlating autoantibody reactivity, and T cell reactivity, with disease
progression in both human and NOD mice, and secondly looking at how
diabetes in the NOD mouse can be modulated following antigen
administration or transfer of antigen-specific T cell clones.

19
A.

Glutamic acid decarboxylase
The above criteria have been used to characterize glutamic acid

decarboxylase (GAD) as a critical (3-cell autoantigen. Its two isoforms, GAD65
and GAD67, are the enzymes that catalyze the formation of the
neurotransmitter, y-aminobutyric acid. Autoantibodies to a 64 kilodalton (kd)
protein were found to be present in diabetic patients in the 1980s (Baekkeskov
et al., 1987). This antigen was subsequently identified as GAD, and is now
used as a predictive marker in pre-diabetic patients (Baekkeskov et al., 1990;
Hagopian et al., 1993). In the NOD mouse anti-GAD T cell responses appear
very early on in insulitis, and prior to the appearance of T cell reactivities to
other (3 cell antigens (including HSP60, and carboxypeptidase H) (Kaufman et
al., 1993; Tisch et al., 1993). Thus anti-GAD activity may be connected to early
events associated with insulitis. Furthermore, NOD mice are protected from
diabetes when they are immunized early on with GAD (Elliott et al., 1994;
Zechel et al., 1998) and seem to undergo a shift from a Thl-like response to a
Th2-like GAD67-specific response. It has also been demonstrated that NOD
mice exhibit spontaneous T cell reactivity to GAD (Kaufman et al., 1993;
Quinn and Sercarz, 1996; Tisch et al., 1993). GAD-specific CD4 T cell clones
have been generated (Schloot et al., 1996), and one such T cell clone has been
shown to cause diabetes in NOD-scid mice (Zekzer et al., 1998). On the other
hand, nasal administration of GAD was found to prevent diabetes, and downregulate T-cell reactivity (Tian et al., 1996). Thus further work is needed in
order to determine the relative contribution and precise role of anti-GAD
reactivity in the disease process.

\
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C.

Insulin
Insulin is secreted, and along with C-peptide, comprises about 80% of

the (3-cell protein (Hutton, 1989). Thus its role as an autoantigen has been of
great interest. It has been studied extensively and in fact appears to play an
important role in diabetogenesis. Antibodies to insulin are found in about
half of recent-onset diabetic subjects, and occur most frequently in children
who have more aggressive (3-cell destruction (Castano and Eisenbarth, 1990).
The first report of insulin-reactive T cell clones was by Wegmann et al
(Haskins and Wegmann, 1996), who isolated CD4 T cell lines and clones from
7 and 12 week old NOD mice, following their culture with islet cells as
antigen. Of the CD4 T cell clones isolated from younger mice 14% of the cells
were reactive to insulin. However, about half of the clones isolated from the
older mice were insulin-reactive, the majority of which expressed a Thl-like
phenotype, and one clone was found to transfer diabetes to NOD-scid mice.
Most of these CD4 T cell clones respond only to the insulin B chain (Daniel et
al., 1995), and NOD mice have shown diabetes resistance following the
administration of this dominant epitope (Daniel and Wegmann, 1996; Muir
et al., 1995). Unlike young NOD mice treated with GAD, histologic
examination of mice receiving insulin continued to exhibit insulitis, which
suggests that insulin reactivity correlates with a later phase of disease
progression. More recently it was shown that the proinsulin II gene driven
off the MHC class II promoter, to direct expression of proinsulin to MHC class
ITbearing cells particularly in the thymus, almost completely prevents
insulitis in transgenic NOD mice (French et al., 1997). Therefore, proinsulin
also appears to play an important role in the pathogenesis of diabetes.
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C.

Other [5-cell autoantigens
Several other p-cell proteins have been identified as T cell antigens.

Autoantibodies and T cell reactivity directed towards heat shock protein
(HSP) have been detected in NOD mice (Elias et al., 1990), and HSP60 reactive
CD4 T cell clones were found to induce disease in NOD mice (Elias et al.,
1991). However, it is not clear whether HSP is a target in human IDDM.
Other target (3-cell autoantigens identified in humans include
carboxypeptidase H, islet-cell antigen (ICA) 69, and the tyrosine phosphatase
IA-2/ICA512, found in the (3-cell granule membrane. ICA512 is an important
though less known ICA (Solimena et al., 1996), and anti-GAD and antiICA512 antibodies together are strongly predictive of diabetes in first degree
relatives of diabetic patients (Bingley et al., 1997).
With the exception of insulin and proinsulin, few other molecules
which are limited in their expression to (3 cells, have been well characterized
(Hutton, 1989). However, evidence for an undefined membrane-associated
antigen has been provided for CD4 islet-specific T cell clones (Bergman and
Haskins, 1994). Subcellular locations of islet antigens were analyzed, and it
was found that a fraction which was highly enriched in (3-cell granules was
antigenic for every T cell clone tested. They subsequently localized that
activity to the (3-cell granule membrane.
Many important questions regarding the nature and role of (3-cell
autoantigens remain to be answered. At present it seems that rather than a
single, organ specific antigen, many antigens play a role in human IDDM and
NOD mice, and many more unidentified (3-cell autoantigens likely exist. One
important unanswered question is whether there exists a primary P-cell
antigen that dominates the induction of diabetes, and if it does exist, will its
identification have therapeutic implications? It seems unlikely that the

I

22
various autoantigens identified thus far could be initiating the same primary
diabetogenic response. Rather, it is likely that a particular type of antigen is
responsible for disease initiation, leading to local inflammation, and
recruitment to the pancreas of islet-reactive T cells with more diverse
specificities (Haskins and Wegmann, 1996).
To date, research has focused on the generation of CD4 T cell clones
that are reactive to previously identified P cell autoantigens. As discussed
above, it now appears that CD8 T cells may be critical initiators of diabetes.
Thus, it is likely that the antigenic targets of CD8 T cell also contribute to
IDDM induction. However, no CD8 T cell antigen has yet been identified in
human or NOD mouse IDDM. Elucidating the nature of CD8 T cell
autoantigens is important for further understanding IDDM in NOD mice and
humans, developing treatment modalities, and may lead the discovery of a
dominant primary diabetogenic antigen.
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Table 1. T cell clones from the NOD mouse (table adapted from Bergman and
Haskins, 1997).
Origin of T cells
Spleen and lymph nodes
of diabetic females
Islet infiltrates of
diabetic females
Islet infiltrates of
diabetic females
Islet infiltrates of 20week old pre-diabetic
females
Three month old female
Islet infiltrates of 8week females (ND)a
Islet infiltrates of 8week females (ND)
Islet infiltrates of 7-10
week old mice (ND)
Islet infiltrates of <10 &
> 10 week old females
(ND)
Islet infiltrates from
irradiated male
recipient
Islet infiltrates of 10-12
week old females (ND)
Islet infiltrates of 4week old females (ND)
Infiltrated islet
allographs
Islet infiltrates of 4 & 7
week old females (ND)
Spleen & lymph nodes of
30-40 day old females
(ND)
Lymph nodes of 6-week
old or diabetic females
Lymph nodes of diabetic
females
Spleen cells of 4-week
nondiabetic females
Islet infiltrates of 7
week old females (ND)
Spleens of 6 week old
diabetic mice,
previously immunized
with GAD

a ND; Non-Diabetic

CD4/CD8

Antigen
specificity

in vivo activity

Investigators

Islet cells, (3
granule
membrane
CD4 &CD8 Islets cells

Insulitis &
diabetes
Insulitis

Haskins et al, 1988,
1989. Bergman &
Haskins 1994
Reich et al, 1989

CD4

Unknown

Protection

Reich et al, 1989

CD8

Islet cells

Not determined

Nagata et al, 1989

CD4
CD4

HSP-65
Islet cells

Insulitis
Protection

Elias et al, 1990
Pankewycz et al,
1991

CD8

Unknown

Insulitis

CD4

Islet cells

Insulitis

Pankewycz et al,
1991
Nakano et al, 1991

CD4 & CD8

Islet cells

CD4 & CD8

Islet cells

Diabetes (CD8
co-transferred
with CD4)
Diabetes (CD4
clones only

Nagata and Yoon,
1992. Nagata et al,
1994
Shimizu et al, 1993

CD4

Unknown

Not determined

Not
determined
CD4

Unknown

Protection

Islet cells

CD4

Islet cells,
insulin
Insulinoma
extracts

Insulitis and
diabetes
Insulitis and
Diabetes
Insulitis

Maugendre et al,
1993
Chosick &
Harrison, 1993
Wegmann et al, 1993

CD4

CD4

Wegmann et al, 1994
Gelber et al, 1994

CD4

GAD-67

Not determined

Elliot et al, 1994

CD4

Islet cells

Healey et al, 1995

CD4

Islet cells

Insulitis and
Diabetes
Protection

CD8

Islet cells

Diabetes

Wong et al, 1996

CD4

Islet cells

Insulitis and
Diabetes

Zeckzer et al, 1998

Akhtar et al, 1995
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7. Measuring T Cell Activation
Overview
T cell activation takes place when a TCR of a circulating lymphocyte
discovers and binds to its peptide/MHC ligand. Many biochemical events,
both cytoplasmic and nuclear take place during T cell activation (Cantrell,
1996). Early cytoplasmic events such as protein tyrosine kinase cascades,
cleavage of inositol phosphate by phospholipase C, and the mobilization of
intracellular calcium stores, lead to the expression of numerous genes
required for T cell proliferation and effector functions. Transcription of the
interleukin II (IL-2) gene occurs early on in T cell activation, and in fact is
thought to be the first committed step of the activation pathway (Crabtree,
1989). Following antigen recognition by the TCR, a transcription factor called
nuclear factor of activation in T cells (NFAT) binds to the promoter region of
the IF-2 gene. The NFAT binding site (Figure 2) is believed to be the most
important response element for TCR-mediated transcription of the IF-2 gene
(Shaw et al., 1988).

A.

Bulk T cell activation assays
The detection and quantitation of T cell activity, and thus any

experimental strategy aimed to identify the peptides recognized by
immunologically important TCRs, has been hampered by the fact that most
T-cell activation assays have low sensitivities. Measuring cytotoxic T cell
activity in vitro includes such techniques as 3H-thymidine proliferation
assays, or in the case of cytotoxic T cells, quantifying killing of target cells via
51Cr-release assays. Assays which quantitate lymphokine production,
including the IF-2, TNF, and INF-y assays, are commonly used. More
recently, the development of calcium sensitive dyes has enabled the
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visualization of calcium mobilization during T cell activation (Poenie et al.,
1987). However, calcium fluxes do not always correlate with T cell activation,
and so calcium levels are not as reliable measure of T cell activity as are the
IL-2, proliferation, and cytoxicity assays (Sussman et al., 1988).
These assays provide a rapid and specific measurement of cytotoxic T
cell activity, yet they have a significant drawback. With the exception of
calcium sensitive dyes, these T cell activation assays detect compounds
released by T cells or APCs into the supernatent, and thus measure the
average activation state of all T cells in the assay. They provide no
information regarding the activation state of individual T cells, and cannot be
used to detect activated T cells when they form only a small proportion the
total T cell population being assayed. This limits the sensitivity of bulk T cell
activation assays for detecting peptide/MHC-expressing APCs .

B.

NFAT lacZ reporter construct and the lacZ assay
In this thesis we have taken advantage of a recently introduced T cell

activation assay (Karttunen and Shastri, 1991), which utilizes a reporter
construct consisting of the bacterial lacZ gene under control of the NFAT
element of the human IL-2 enhancer (Figure 2). The lacZ gene encode (3galactosidase, an enzyme that acts on chromogenic substrates such as 5bromo-4-chloro-3-indolyl-(3-D-galactopyranoside (X-gal). LacZ activity is
induced in T cells by the interaction with peptide/MHC ligand, and parallels
IL-2 expression. Once activated, T cells transfected with the lacZ reporter
express uniformly high levels of (3-gal and turn blue in the presence of X-gal.
This enables the detection of individual activated cells, even when they are a
small fraction of the total T cell population. This additionally allows for the
detection of rare APCs which express the activated T cell's target antigen.

IL-2 gene. (Figure from Fiering et al., (1990) Genes and Development 4:1823-1834.)

Figure 2. Diagrammatic structure of the NFAT-/ucZ reporter construct, using the enhancer/promoter of the human
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8. Strategies for identifying T cell antigens
Overview
There are two general strategies for the identification of the peptideMHC ligands recognized by T cells: biochemical purification of MHC-bound
processed peptides, and expression cloning of the antigenic genes. Both
approaches require that the MHC-peptide ligand be expressed on the surface
of APCs, and be detectable by a T cell activation assay.

A.

Biochemical purification of antigens
T cell antigens can theoretically be identified by directly purifying

naturally processed and presented MHC-bound peptides from target APCs.
However, biochemical purification is difficult not only because MHC
molecules display thousands of different peptides on the cell surface (Falk et
al., 1991; Hunt et al., 1992), but also because only a few copies of individual
antigenic peptides may be presented per cell (Cox et al., 1994; Kageyama et al.,
1995). In addition, it is noteworthy that the peptide purification strategy
requires sophisticated instrumentation, (such as a high pressure liquid
chromatography (HPLC) system and a mass spectrophotometer), not to
mention experimental and analytic skills that are not available in many
laboratories.
Nevertheless, several groups have overcome these difficulties and
have identified the antigenic ligands of some T cells using HPLC. Eisen and
co-workers identified the peptide component of the 2C ligand alloantigen
(graft rejection antigen) recognized by C57BL/6 T cells on BALB/c mouse
tissue (Udaka et al., 1992; Udaka et al., 1993). A human alloantigen associated
with HLA-A2.1 class I molecule (Henderson et al, 1993), as well as a peptide
recognized by melanoma-specific human cytotoxic T cell lines (Cox et al..
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1994), were similarly isolated by Hunt and colleagues. However, unlike
alloantigens and tumor cell proteins which can be relatively abundant, most
immunologically important peptides, including those involved in
autoimmunity, are present at very low frequencies on cell surfaces, and have
been resistant to isolation by this approach.
The identification of autoantigens in type 1 diabetes using biochemical
analysis is particularly difficult because the isolation of mouse islets is a very
expensive and labor intensive endeavor. The typical yield from a NOD
mouse pancreas is in the order of 105 islet cells. Thus the biochemical
purification of islet cell proteins, which requires in the order of 1010'12 islet
cells (Shastri, 1996), is not feasible without a tumor cell source.
Unfortunately, tumor cell lines are known to undergo a variety of changes
when kept in culture, and tend to quickly lose their antigenicity. Researchers
who have attempted to identify T cell antigens using biochemical techniques
have thus needed to use mouse strains that produce (3-cell tumors
(insulinomas) (Bergman and Haskins, 1997).

However, this antigenic source

may similarly not be representative of the proteins naturally existing in NOD
mouse islets.

B.

Expression cloning of T cell antigens
In contrast to biochemical purification, expression cloning strategies are

not dependent upon the total amount of obtainable peptide, but upon the
construction of representative cDNA libraries, the efficient expression of
candidate antigen genes, and the generation of appropriate peptide-MHC
ligands on the APCs. The much smaller amounts of tissue required to make
a cDNA library, as compared to the amount needed to purify adequate
quantities of peptides, is especially useful when antigen-expressing tissue, as
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with the pancreatic islets of NOD mice, is particularly difficult to obtain. Not
only does this approach require less starting materials, the DNA
manipulations required for expression cloning are now routinely available in
most laboratories (Shastri, 1996). For these reasons we have chosen to use
expression cloning, rather than peptide purification as a means to identify the
islet cell antigen of our diabetogenic CD8 T cell clones.

C.

Expression cloning of a CD8 T cell antigen
The isolation of CD8 T cells and identification of their autoantigenic

peptides is a difficult task. Thus very few CD8 clones have been generated,
and their target antigens have remained elusive (Nagata et al., 1994;
Santamaria et al., 1995; Shimizu et al., 1993). The primary difficulty with
identifying T cell antigens, which relies on the detection of ligand-induced T
cell activation, arises from the fact that neither the TCR nor its peptide/MHC
ligand exist functionally in a soluble state. Since both the receptor and its
ligand are membrane-bound, screening for a T cell antigen must rely on
cellular assays, the majority of which are inherently insensitive, and cannot
detect small populations of activated T cells. The work of Jaana Karttunen in
developing the LacZ assay further suggested an expression cloning strategy
that exploits the highly sensitive lacZ inducible T cell hybrids (Karttunen et
al., 1992; Sanderson and Shastri, 1994). This cloning strategy, originally
developed by Aruffo and Seed, is based on the transient expression of
candidate cDNAs in COS cells (Aruffo and Seed, 1987a, 1987b).
COS cells are transformed cell lines generated by the transfection the
CV-1 simian fibroblast line with an origin defective mutant of the SV40 virus
(Gluzman, 1981). These cell lines stably express the SV40 large T antigen. As
such they are capable of replicating circular DNAs containing the SV40 origin

_
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of replication, and attain very high levels of protein expression. Using the
lacZ assay, it has been shown that COS-7 cells can function as APCs for the
detection of rare antigens found in the primary screen of expression libraries;
antigen-expressing COS-7 cells can be detected at frequencies of 1:103 to 1:104
(Karttunen et al., 1992). Since T cells recognize peptide in the context of selfMHC molecules, COS cells must first be stably transfected with the relevant
MHC molecule.
We are applying this expression cloning system as a means to identify
the nature of the antigen recognized by the CD8 cell lines in young NOD mice
(Wong et al., 1996). The system consists of lacZ inducible T-cell hybrids
specific for the unknown antigen, and a COS cell line expressing the relevant
MHC. In this case the H-2Kd restriction element recognized by the CD8 T cell
clones has been stably transfected into COS-7 cells (Kd-COS). These APCs, in
the presence of lacZ inducible hybrids, were used to screen a cDNA library
that was generated from normal islet (3 cells which express the autoantigen
(Figure 3).

Statement of purpose
The definitive identification of the autoantigens involved in IDDM is
an important initial step in sorting out the series of events leading to the
acquisition of the disease. Despite significant efforts to identify the specific
antigenic peptide recognized by an individual TCR, this has remained a
difficult undertaking. The primary reason for this difficulty lies in the
inherent lack of sensitivity of the bulk T-cell activation assays used to detect
peptide/MHC-expressing APCs. These assays only measure the average state
of activation within a given T cell population, and thus cannot detect
activated T cells when they constitute only a small percentage of the total T

1
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cells being assayed. The research presented here is the screening of an
expression cDNA library made from normal NOD mouse islets which express
the autoantigen of cloned CD8 T cells, obtained at an early stage of disease in
NOD mice. This requires the ability to detect ligand-bearing APCs when they
are present at very low frequencies. In recent years a method for detecting
individual ligand-activated T cells that are stimulated by correspondingly rare
MHC class I restricted APCs has been developed. This method has been used
here as an expression cloning strategy for identifying the target antigen(s) of
the diabetogenic G9 CD8 T cell clone.
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Islet cDNA

Plasmid expression vector

SV40 replication origin

Kd
Kd COS cell

Kd + peptide

Figure 3. Schematic illustration for processing and presentation of transiently
expressed proteins by Kd-COS cells to the BW/G9 T-cell hybrid.
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Materials and Methods

1. Cell culture
COS-7 cells (ATCC) are maintained on Dulbecco's minimum essential
medium (DMEM) supplemented with 10% fetal bovine serum, 2 mM
glutamine, 1 mM pyruvate, penicillin (200 units/ml), streptomycin (200
ug/ml), and streptomycin (200 fig/ml). Kd-COS cells were maintained on
DMEM with supplements, plus 1 pg/ml G418 (Geneticin). T cell hybrids are
maintained on Click's with 10% fetal bovine serum, plus antibiotics. All cells
are kept at 37°C in a 9% C02/91% air atmosphere.

2. Cell lines.
As indicator T cells, this system uses a-P-BW5147 cells, transfected with
the NFAT-/acZ construct by electroporation (obtained from Dr. N. Shastri).
These cells were transfected with a CD8a retrovirus and have been fused to
the diabetogenic CD8 T cell clone G9 (Wong et al, 1996), generating hybrid
BW/G9 cells which express the V(36 TCR as well as CD8 and CD3, together
with the lacZ gene driven by the NFAT promoter.
COS-7 cells were obtained from ATCC. The cells were stably transfected
with a genomic clone of the murine H-2Kd molecule, kindly provided by J.
Karttunen (Yale University School of Medicine). Using the Superfect
transfection reagent (see below), COS-7 cells were transfected with Kd plasmid
along with a co-selection marker pMCllneo-polyA+ plasmid which confers
neomycin resistance. Transfectants were selected in 1 jag/ml of G418
(Geneticin), and Kd expressing COS cells were isolated by fluorescenceactivated cell sorting (FACS). The most highly expressing Kd~COS cells were
selected and subsequently cultured.
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3. Transfection protocols
COS-7 cells were transfected using Superfect (Quiagen) which
represents a new class of polycationic transfection reagent, and offers high
efficiencies and reproducibility, with minimal toxic effect. Stable or
permanent transfection was carried out using adherent COS cells that were
50% confluent in 50 ml tissue culture flasks. 10 pg of DNA, complexed with
Superfect, was transferred to the COS cells. The cells and complexes were
incubated for 2 to 3 hours at 37°C in 5% CO2 atmosphere. They were then
washed 4 times with 10 ml of PBS, covered with fresh growth medium, and
incubated for 24 hours. Transfectants were subsequently selected with 0.5
pg/ml G418 for 24 hours, followed by 1 pg/ml G418.
The same protocol was used for transient transfections, though it was
modified for use in flat-bottomed 96-well plates. Approximately 1 x 104 KdCOS cells per well were plated the day prior to transfection. For each plate, 35
pg of DNA and 150 pi of Superfect reagent was allowed to complex in 750 pi of
antibiotic and serum free DMEM. Following incubation, this mixture was
brought to a total volume of 6 ml with appropriate medium, and 50 pi of the
mixture was then dispensed into each of the 96 wells of washed Kd-COS cells.
The cells and DNA-Superfect complexes were incubated for 2-3 hours at 37°C
in 5% CO2 atmosphere, washed 3 to 4 times with 150 pi of sterile PBS and
then covered with 100 pi of growth medium per well. Plates were incubated
for 48 hours before being assayed for lacZ activity.
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4. FACS staining
Kd-COS cells were stained for FACS analysis using the monoclonal
antibody HB159 (anti-H-2Kd). About 105 transfected cells, and untransfected
control COS-7 cells, were each incubated in the dark for 30 minutes at 4°C
with the primary HB159 antibody (diluted 1:200). Cells were then spun at 2000
rpm for 5 minutes, washed once with staining buffer, and respun. The
secondary antibody, anti-mouse IgG (FC specific) FITC (diluted 1:500), was
then added to the cells, which were again incubated for 30 minutes in the cold
and dark. Finally, the stained cells were spun down and fixed with 1%
paraformaldehyde.

5. cDNA library construction
The cDNA library of NOD mouse islet [3 cells, containing the mRNA of
the unknown peptide, was made using 12 jug of NOD islet mRNA. The
mRNA was extracted from the islets of 200 young male NOD mice (work
performed by M. Altieri). The islets were isolated by collagenase digestion
and purified on Percoll density gradients. Total RNA was extracted using
Trizol reagent (Gibco) and mRNA was further purified using a poly A
column (carried out by S. Wong). The cDNA library is an unamplified
library, and consists of > 3 x 107 primary transformants, which are DH10B
bacterial cells. The library was provided in sixty, 1 ml pools each containing >
5 x 105 clones (synthesized by Edge Biosystems AGTC, Maryland). The library
was constructed in the expression vector pEAX, which contains the SV40
origin of replication for plasmid expression in SV40 large T antigen¬
expressing COS cells (Figure 4). The average cDNA insert size is 1.31
kilobases, and the insert cutoff size is 700 base pairs.

36

Sequence flanking cloning site of pEAX
2701

CTGAAGTTAG GCCAGCTTGG CACTTGATGT AATTCTCCTT GGAATTTGCC

2751

CTTTTTGAGT TTGGATCTTG GTTCATTCTC AAGCCTCAGA CAGTGGTTCA

2801

AAGTTTTTTT CTTCCATTTC AGGTGTCGTG AA AAGCTT GA
ATTC GGCGCG
Hind III
EcoR I
Asc I

2851

CCA GATATC A CACGTG CCAA GGGGCTGGfcDNA 5'EcoR V

Pml

I

3'}CA CCTGGCCTGC

Bst XI

AGGCGGCCGC
Not I
2900

AGGTAAGCCA GCCCAGGCCT CGCCCTCCAG CTCAAGGCGG GACAGGTGCC

2951

CTAGAGTAGC CTGCATCCAG GGACAGGCCC CAGCCGGGTG CTGACACGTC

3000

CACCTCCATC TCTTCCTCAG GTCTGCCCGG GTGGCATCCC TGTGACCCCT

3051

CCCCAGTGCC TCTCCTGGCC CTGGAAGTTG CCACTCCAGT GC

Figure 4. pEAX vector of the islet cDNA library, and the sequence cloning site
of pEAX.
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6. COS cell transient expression assay
Individual cultures of H-2Kd-COS cells, transiently transfected with
pools of cDNA, were set up in 96-well plates. The cells were incubated for 48
hours to allow expression of the introduced genes. After 24 hours, about ten
NOD mouse islets were added to each of ten wells of the negative control
plate (see below). Another 24 hours later, 2 X 104 G9 T cell hybrids per well
were added to the transfected COS cells to give a total volume of 0.2 ml per
well.
The T cell hybrids were co-cultured overnight with cDNA-expressing
Kd-COS cell, and then fixed and stained with 5-bromo-4-chloro-3-indolyl-(3-Dgalactopyranoside (X-gal) (Sigma). Plates were washed once with 0.1 ml of
PBS per well, spun for 1 minute at 2000 rpm, and then fixed for 5 minutes on
ice with 0.1 ml of ice-cold 2% formaldehyde/0.2% gluteraldehyde in PBS per
well. After another wash with PBS and spinning, the cells were overlaid with
a solution of 0.5 mg/ml of X-gal, 5 mM potassium ferrocyanide, 5 mM
potassium ferricyanide, and 2 mM MgCl2. After an overnight incubation at
37°C, the plates were then examined microscopically for blue (lacZ expressing) hybrid T cells.

7. cDNA Library Screening.
Having generated both the expression library and indicator T cells,
large pools of cDNA's were screened for autoantigen-expressing APCs. This
method has been shown to detect ligand-expressing APC's at minimum
frequencies of 1 in 103 (Karttunen et al., 1992). Large pools containing 5 x 105
cDNAs were initially screened. Since NFAT-mediated transcriptional activity
is an early event in T cell activation, the lacZ response is detectable within 6
hours.
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Controls were included in each set of transfection assays. Negative
controls consisted H-2Kd COS cells transfected with P022, the DNA sequence
of ovalbumin. T cell hybrids, incubated with irradiated NOD mouse islets
and control-transfected COS cells for 24 hours, served as positive controls.
When wells contained clusters of blue cells, or a significantly greater number
of blue cells in a well than the negative control plate, they were treated as
potentially positive pools; that is, the cluster of blue hybrids had been
activated by a peptide presented by the transfected COS cells.
Each potentially positive pool was further tested for the presence of an
activating message using the process of limited dilution (Figure 5). After
several subdivisions a pool with approximately 200 cDNAs was obtained.
From these small pools, the plasmid cDNA from single, hand-picked bacterial
colonies were purified and transfected into single wells of Kd-COS cells.
When individual cDNA plasmids expression in Kd-COS cells led to the
activation of significant numbers of BW/G9, the cDNAs were identified as
candidate antigens. In order to define their nature they were sequenced, and
compared to known gene and amino acid sequences using the NCBI database
and Swiss protein database, respectively. Subsequently, the minimal peptide
determinants within these sequences were identified by comparing them to
Kd-specific motifs (Falk et al., 1991), which are defined by a tyrosine residue at
position 2, and leucine or isoleucine at position 9 of the peptide. These
sequences are then used to synthesize the minimal peptides.

The

antigenicity of these peptides was subsequently evaluated using proliferation
and 51Cr cytotoxic assays with G9 T cell clones, as well as in LacZ assays with
Kd-COS cells and BW/G9 hybrids.

Islet cDNA library in COS cell expression vector

O Oo
Divide library into pools

Transfect each pool into COS cells
expressing the

MHC molecule.

48 hours
y
Screen for COS cells expressing unknown ligand by co¬
culturing with lacZ inducible T cell hybrid.

12 hours
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Pool 2

Pool N

Further sub-divide positive pool(s)
and repeat screening procedure.

Figure 5. Schematic illustration summarizing the strategy for expression
cloning of T-cell antigens.
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8. cDNA pool subdivision
Pool subdivisions were accomplished by transforming XL-1 blue
electroporation-competent cells (Stratagene, California). The original 60 pools
each contained 5 x 105 cDNAs in bacteria. Xl-1 blue cells were transformed by
electroporation with DNA such that ten fold fewer (ie. 5 x 104) colony forming
units (CFUs) each receiving a different cDNA plasmid, grew on each of ten 15
cm x 15 cm Luria-Bertani (LB) agar containing 40 pg/ml ampicillin plates.
The XL-1 blue cells were thawed on ice, of which 40 pi was mixed with diluted
DNA. Cells were transferred to a chilled 0.4 cm-gap electroporation cuvette,
and pulsed once with 2500 volts on a Bio-Rad electroporator, set at a
resistance of 200 Ohms and capacitance of 25 pF. 960 pi of LB was immediately
added to the cells, which were then allowed to recover for 1 hour at 37°C
before being plated (96 pi/plate) as described above.
Bacterial colonies were scraped off the plates, resuspended, and plasmid
DNAs purified using the TENS mini-prep method for use in subsequent
transfections of H-2Kd COS cells. Since the pools were ten-fold smaller, they
were screened with the lacZ assay in only a third of a 96-well plate. This
process of limited dilution was repeated each time a positive signal was
identified in a subdivided pool.
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Results

1. Stable transfection of COS cells with the H-2K^ MHC class I
molecule yields Kd expressing APCs.
In order to screen the islet cell cDNA expression library, we took
advantage of the well-developed transient expression system present in COS7 cells (Aruffo and Seed, 1987; Aruffo and Seed, 1987) as described by
Karttunen and Shastri (1991). COS cells are transformed cell lines generated
by transfecting the CV-1 simian fibroblast line with an origin-defective
mutant of the simian virus 40 (SV40). These cell lines express the SV40 large
tumor antigen and support the replication of circular DNA containing the
SV40 origin.
In order to generate a COS cell line that can present peptides/Kd ligands
to the Kd class I MHC-restricted T cell hybrids, COS cells were stably
transfected with the Kd molecule. The Kd-expressing COS cells (Kd-COS) were
analyzed by flow cytometry and found to express Kd at high levels (Figure 6).
Though the ability of Kd-COS cells to present endogenous proteins to BW/G9
hybrid cells was not tested, it has previously been determined that Kb-COS
cells process and present transiently expressed ovalbumin (OVA) to an
OVA/Kb restricted T cell clone (Karttunen et al., 1992). This demonstrates
that cDNA plasmids are expressed and presented to T cells by COS-7 cells, and
that COS-7 cells can function as efficient APCs for MHC class I-restricted NOD
mouse T cells (diagrammed in Figure 3).

Figure 6. COS-7 ceils transfected with MHC class I molecule H-2Kd, express Kd
on their surface, as shown by staining with anti-Kd antibody HB519 (-), as
compared to untransfected COS cells stained with anti-Kd (.).
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2. Microscopic detection of lacZ -inducible T-cell hybrids in the
presence of NOD mouse islets and the chromogenic substrate X-gal.
The analysis of Kd-COS cells transfected with islet cDNA was
performed using the /acZ-expressing T cell hybrids. Indicator T cells were
visualized by staining with the chromogenic substrate, 5-bromo-4-chloro-3indolyl-(3-D-galactopyranoside (X-gal). X-gal is cleaved by (3-galactosidase to
yield 5,5'-dibromo-4,4'-dichloroindigo, which stains the lacZ -expressing T
cells dark blue. It has previously been demonstrated by Karttunen et al (1992)
that X-gal staining, used as a semi-quantitative or qualitative assay, is very
sensitive for detecting activated, /acZ-expressing T cells, and therefore their
corresponding ligand-expressing APCs. In those studies, ligand expressing KbCOS cells were detected at a frequency of 1:103, when assayed in triplicates
(Karttunen et al., 1992).
The photomicrograph of X-gal-stained control samples, shown in
figure 7, illustrate how activated focZ-expressing BW/G9 T cell hybrids are
visualized as darkly staining blue cells, and are easily distinguishable from
background, yellow APCs and non-activated T cell hybrids. Figure 7
illustrates that BW/G9 T cell hybrids are islet specific; they turn blue in the
presence of NOD mouse islets, which serve as a positive control for the
LacZ/COS cell assay. As a negative control, BW/G9 cells are co-cultured with
ovalbumin-expressing Kd-COS cells transfected with the OVA (P022) gene,
and rarely turn blue (Table 2). The negative control illustrates that BW/G9
cells do turn blue in the absence of the antigen, and this represents
background lacZ activity that is significantly less than that seen with clones
cultured in the presence of antigenic islets.
It was observed that with time BW/G9 T cell hybrids gradually lost
their ability to turn blue in the presence of islets. Hybrid T cells tend to
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Figure 7. LacZ-inducible T cell hybrids turn blue in the presence of islets and
the chromogenic substrate X-gal. Arrows indicate activated (blue) cells
surrounding a NOD mouse islet.
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proliferate extremely rapidly, and after 4 or 5 weeks in culture have passed
through many cycles of cell division. It is unclear why the /tfcZ-expression of
T cell hybrids became less inducible with time, though it may be related to the
observation that T cell hybrids are inherently unstable. They tend to lose
their TCRs, which would result in decreased reactivity to their ligands after
several generations in vitro. Thus, T cell hybrids were discarded after about a
month of culture, and fresh batches of frozen T cell hybrids were thawed and
used in future assays. In addition, the background lacZ activity seen in the
negative control assays was highest with newer T cell hybrids. The frequency
of background X-gal stained T cells gradually decreased with time, thus
paralleling the decrease in T cell activity seen in the positive controls.

3. A pool of islet cDNA induces lacZ -expression in BW/G9 T cell
hybrids.
Using the lacZ/COS cell assay all 60 pools each containing about 5 x 105
unique cDNA were screened. One pool of the islet cDNA library, when
transfected into Kd-COS cells, appeared to induce increased lacZ activity in the
islet antigen-specific T cell hybrids; about 20 blue cells per well, versus 2-3 blue
cells per negative control well (Table 2). The antigenicity of the cDNA pool
was suggested by the fact that there were increased numbers of blue, X-gal
stained cells as compared to the negative control. However, although all of
the T cells turned blue with equal intensity, the number of /acZ-expressing T
cells in this pool did not approach that seen in the positive control. When
this pool was subdivided into ten, smaller pools each containing 5 x 104
transformants, and re-screened, similar numbers of activated T cells (about 510 fold more than the negative control) (Table 2) were again visualized.
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Table 2. Representative numbers of lacZ expressing (blue) indicator T cells
per well of potentially positive cDNA pools, and corresponding numbers in
control (P022 expressing) wells. Counts are either numbers of clustered blue
cells or the average number of blue cells/well in 5 wells.
cDNA pool #

# blue cells/well

# blue cells/control well

6

10 (cluster)

1-2

14

6 (cluster)

1-3

24

12 (cluster)

2-3

24 (s.d.)a

40

3-4

24 (s.d.)

36

3-4

fls.d.; subdivided

Thus, we continued this process of limited dilution, each time subdividing
the pool which had yielded the most numbers of activated BW/G9 cells.

4. Establishing the antigenicity of candidate cDNAs
When a pool size of about 2 x 102 colonies was reached, individual
cDNAs were transfected into wells of Kd-COS cells, and screened. Several
such candidate cDNAs were associated with a 10-fold increase in lacZ activity
above background, and were selected as candidate antigenic cDNAs,
sequenced, and compared to known gene and amino acid sequences using the
NCBI database and Swiss protein database, respectively. Three of these
cDNAs were identified as the mRNAs coding for amylase, pre-proglucagon,
and pre-proinsulin. However, when the corresponding peptides of known
Kd motifs within these genes were tested for their antigenicity on Kd-COS
cells and NOD spleen cells using proliferation assays with G9 clones, as well
as lacZ assays with BW/G9 hybrids, no T cell activation was detected.
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Furthermore, they candidate genes were re-tested by transfecting the cDNA
into Kd-COS cells and again no significant (3-gal activity was detected in co¬
cultured T cell hybrids. Thus the G9 clones do not appear to be recognizing
known Kd motifs within these proteins. However, it may be that
unconventional Kd binding peptides exist within proteins such as pre¬
proinsulin, and these can perhaps be determined using a peptide scan
technique.
Other known (3-cell autoantigens were previously tested, in the form of
peptides, for their antigenicity to the G9 T cell clones, using IL-2 proliferation
assays and cytotoxic 51Cr-release assays. GAD65 and GAD67 were tested and
not found to induce T cell activation. The antigenicity of insulin, proinsulin,
and preproinsulin were additionally tested using these assays, as well as by
directly adding peptides to the supernanent of Kd-COS cells co-cultured with
BW/G9 T cell hybrids, and applying the lacZ assay. The peptides did not
activate the T cell clones or hybrids, and thus do not appear to be the ligands
recognized by these CD8 T cell clones.
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Discussion

1. Islet cell cDNA library
Expression cloning of antigenic peptides, as an alternative to
biochemical purification, is not dependent upon the total amount of
obtainable protein, but requires the extraction of relatively large amounts of
highly purified mRNA from the appropriate tissue, for the cDNA library
construction. Thus, the availability of high quality starting material is critical
for successful expression cloning strategies. The construction of this islet
cDNA library used mRNA purified from the islets of 200 non-diabetic male
NOD mice. The library is an unamplified library prepared from stringently
size-selected cDNA (Edge Biosystems, Maryland). Although this cDNA
library has been skillfully constructed from excellent starting materials, it can
be that target antigens are resistant to cloning, as when they are too large (ie. >
5 kb in size), or too small. The cut-off size of the islet cell cDNA library used
in this study is 700 base pairs. Thus the cDNAs corresponding to very small
proteins could be excluded from this library.

2. MHC class I expressing COS cells and the lacZ expression cloning
strategy.
In this thesis we are applying a newly described expression cloning
strategy in an effort to identify the antigen recognized by the diabetogenic CD8
T cell clone. Here we show that COS-7 cells can stably express the NOD
mouse Kd MHC class I allele at high levels (figure #). Our prediction that
COS cells could function as APCs for NOD mouse Kd-restricted T cells was
based on previous findings that the mouse Kb Class I molecule can interact
appropriately with the simian antigen processing machinery existing in COS
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cells (Karttunen et al, 1992). It was determined that OVA expressing Kb-COS
cells activated a murine OVA/Kb-specific T cell, and that the peptide
generated by the K^-COS cell was identical to the peptide generated by OVA
expressing mouse cells. Furthermore, studies of antigen-MHC ligands have
not revealed any instances of species specific antigen processing and peptide
formation, suggesting that the antigen processing machinery is highly
conserved amongst mammals (Falk et al., 1991; Karttunen et al., 1992).
Therefore, it seems likely that we are using an expression cloning system
which generates peptide-Kd ligands on transfected Kd-COS cells that would be
identical to the peptides generated in similarly transfected Kd expressing
mouse cells. Here we are assuming that the presence of the appropriately
restricted MHC molecule is sufficient for the appropriate generation of
peptide-Kd ligands.
Despite the compatibility seen between the murine Kd MHC class I
molecule and the COS cell's simian antigen processing machinery, it is
important to consider the possibility that certain peptides may be resistant to
processing and presentation of the Kd Class I pathway by COS cells. In order
to demonstrate that Kd class I molecules process and present transfected
cDNA appropriately in COS cells, we will determine whether Kd-restricted
CD8 T cells, specific for the listeria P60 protein, are activated when co-cultured
with Kd-COS cells transiently transfected with the P60 gene (provided by E.
Pamer, Yale University School of Medicine). This model does not however
directly test the ability of the G9 T cell clone to bind and become activated by
peptide-Kd ligands on COS cells, and we would need to assume that our
clone's TCR functions identically to that of the P60-Kd specific clone.
This P60-Kd model will not only determine if the mouse Kd Class I
molecule interacts appropriately with the COS cell's antigen processing
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machinery, but will also serve as a marker for successful transfections during
the islet library screening process. The timely screening of 107 clones in the
islet library required the semi-synchronous transfection of many cDNA pools.
As a result COS cells were not consistently exposed to the Superfect reagent
for the same length of time. Over-exposure to the Superfect reagent is
damaging to cells. Therefore some pools may have been transfected for suboptimal amounts of time, whereas others may have been transfected for too
long, and therefore damaged. This variation in transfection efficiency could
be monitored using the P60-Kd-specific T cells and P60 expressing Kd-COS,
and the most efficient transfection time-span could be determined.

3.LacZ -inducible BW/G9 T cell hybrids
A.

Increasing the sensitivity of the lacZ assay
As an alternative to conventional T cell activation assays, the

particular strategy used here takes advantage of an NFAT-lacZ reporter which
has been incorporated into the BW5147 fusion partner. BW cells were fused
to the diabetogenic CD8 T cell clone, G9, to generate lacZ-inducible BW/G9 T
cell hybrids. Here we demonstrate that when activated by NOD mouse islets,
BW /G9 hybrids express the lacZ gene, and turn dark blue in the presence Xgal (figure 7). As such, these hybrids have been used as a single T cell
activation assay to probe for ligand expression on APCs. Previously, this assay
has been shown in the model system using ovalbumin, to be sufficiently
sensitive to allow the detection of OVA cDNA at a frequency of 1:103 - 104
(Karttunen et al., 1992). Here we used lacZ-indicator BW/G9 to probe for
antigenic cDNAs in large pool sizes of 5 x 105 cDNAs. Assuming that the
BW/G9 hybrids are as sensitive as the OVA specific B3Z indicator cells, and
that the autoantigenic cDNA is abundant in the library, then our primary
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screen should detect the peptide-ligand within these pools. However, at this
point we have screened the entire library divided into 60 such pools, and no
potentially positive signal has led to the identification of an antigenic cDNA.
This represents an inherent difficulty that can be encountered with
expression cloning strategies, where the target mRNA is rare and poorly
represented in the islet cell library, and thus remains undetected by indicator
T cells during the primary screening of very large pools of cDNA.
This difficulty can be addressed in two ways. First, the library screening
can be carried out using smaller pools of cDNA, and we have begun the
process of subdividing large pools into ten-fold smaller (104 cDNA) pools of
cDNA. This will increase the proportion of candidate cDNAs within each
pool, bringing their frequency into a range that the T cell hybrids are able to
detect. However, this also creates a ten-fold increase in the number of pools
to be screened, significantly increasing the time and effort involved in
screening the library. The second approach is to increase the sensitivity of the
BW/G9 hybrids. Since we do not know the antigen-specificity of the T cell
hybrids (that is what we are determining), we cannot directly measure their
sensitivity. Yet, it is possible to evaluate the BW/G9 hybrids' general
reactivity through their co-culture with target tissue (ie. pancreatic islets),
assuming that the T cell ligand is expressed at consistent densities on islet
cells. It can be expected that the more sensitive the hybrids are the more will
turn blue in the presence of islets. Recently, findings indicate that the
efficiency of the NFAT-/flcZ reporter construct varies depending on where it
is incorporated into the indicator cell's genome (J. Karttunen, personal
communication). The BW hybrid partner used here already contained the
reporter construct in the DNA at the time it was fused to the G9 clone. Thus,
the most highly islet-reactive BW/G9 hybrids were selected for, but with the
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lacZ reporter fixed in one position. Thus, an approach to increasing the
sensitivity of the indicator T cell hybrids is to first fuse the G9 clone to the BW
fusion partner, without the lacZ reporter, and select for the BW/G9 hybrids
most highly activated by islets. Following this, the NFAT-/acZ reporter
construct can be transfected into these hybrids, where once again the most
highly /acZ-expressing cells are selected for.

B.

Pursuing a potentially positive signal by limiting dilution
By far the biggest undertaking in the screening of a library is the task of

identifying a primary pool of cDNA which contains the sought after antigen.
This is because many factors, such as the abundance of autoantigen cDNA,
and the sensitivity of indicator T cells, which are contingent on the feasibility
of the expression cloning strategy, are unknown. However, once a positive
pool is identified, the process of limiting dilution should facilitate the further
identification of positive, sub-divided pools. This is because the candidate
cDNAs are more highly represented in successive subdivisions, and should
yield increased levels of lacZ activity in indicator T cells. In fact, it has been
suggested that soon after the enrichment of a pool containing antigenic
cDNAs, a positive signal could exponentially increase from a rare cluster of
blue cells to the generation of many ZacZ-positive wells, similar to those seen
with islet-activated hybrids (Karttunen et al., 1992). However, this is not clear
with our BW/G9 hybrids. We did not observe this phenomenon when a
potentially positive pool, which had yielded a small cluster of blue cells, was
pursued by limiting dilution. The lacZ activities remained only slightly
greater (about 10 fold more blue cells) than background levels on subsequent
sub-divisions. It may be that this was a false positive signal. On the other
hand, attaining large increases in a signal may be possible only when the
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antigen is expressed at levels found in vivo. This level may be very high, and
may be reached only using small pool sizes at the end of the dilution process.
For these reasons, we pursued this potentially positive signal until individual
cDNAs were isolated and tested for their antigenicity.
Pursuing a potentially positive signal in the absence of further feedback
information (ie. confirming that the signal is real) risks investing a
tremendous amount of time and effort into the isolation of candidate cDNAs
which are not the true autoantigens recognized by the indicator T cell.
Therefore, it would be extremely useful to have a second equally sensitive
assay, which can be used concomitantly with the lacZ assay, to substantiate a
potential positive signal. For instance, the G9 T cell clone itself is very
sensitive, and proliferates efficiently in the presence of islets. The clones
could perhaps confirm a positive lacZ assay by using proliferation and/or
cytotoxic assays with the pool in question. It must be noted, however, that as
with T cell hybrids, these clones can proliferate non-specifically, generating
background signals which are difficult to distinguish from weakly positive
signals. Alternatively, Boon and colleagues have successfully identified the
antigens of several tumor-specific CD8 T cells (Boon et al., 1989). They have
done so using an expression cloning strategy where the library was screened
in stably transfected APCs and tested for their ability to stimulate tumor
necrosis factor (TNF) release by cytotoxic CD8 T cells (Traversari et al., 1992;
van der Bruggen et al., 1991). Though stable transfections, as compared to
transient transfections, take longer to establish, such an approach may prove
useful as a second assay to confirm positive signals generated by the lacZ
assay.
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C.

Stability of lacZ-inducible BW/G9 hybrids
It was observed that after several weeks in culture BW/G9 T cell

hybrids would gradually lose their islet-cell reactivity. The BW fusion
partner of these hybrids is an immortalized cell which allows the hybridomas
to multiply indefinitely. As a result, T cell hybrids tend to proliferate
extremely rapidly, and undergo many cell divisions over short periods of
time. As with many tumor cell lines, T cell hybrids are inherently unstable
cells, and over time tend to lose essential surface molecules including their
TCRs, CD8, and CD3 molecules. During the screening, it was also observed
that as with the positive controls, hybrids had less background LacZ activity
over time. Having decreased non-specific background fortunately
compensated for the fact that the T cell hybrids also became less sensitive with
time. Furthermore, as a means of maintaining islet-reactive hybrids in
culture, frozen stocks of new hybrids were thawed to replace old hybrids every
fourth week. Nonetheless, the gradual loss of T cell reactivity from one
weekly set of transfections to the next does add some degree of variation to
the sensitivity of our T cell probe. Since the feasibility of expression cloning
requires that the lacZ assay be sensitive enough to detect antigen-expressing
APCs at low frequencies, it would be advantageous to use indicator cells that
did not tend to lose their reactivity to antigen. One option is to incorporate
the lacZ reporter construct directly into the T cell clones, which proliferate
indefinitely when cultured with islets, and have no propensity to lose their
sensitivity to antigen over time. These highly responsive clones could then
be used to screen for their autoantigen using a lacZ assay. The successful
development of such indicator T cells would however be limited by the fact
that T cell clones are notoriously difficult to permanently transfect (S. Wong,
personal communication).
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4. Nature of the autoantigenic target of CD8 T cells, cloned from
young NOD mice.
A. Confirmation of peptide antigenicity
Following the isolation of candidate cDNAs by limiting dilution, they
will be sequenced in order to identify the nature of the antigen. These
sequences can then be used to isolate and characterize the genomic DNA
sequences of these genes. As described in the results section, follow-up
experiments with these candidate antigens can then done in order to establish
their antigenicity. Identifying the cDNA and thus the amino acid sequence of
candidate antigens will allow the construction of the minimal peptide
determinants within the autoantigen sequence, based on the motifs specific
for the Kd reported by Ramensee and colleagues (Falk et al., 1991). This will
allow the identification of the peptide antigen in a functional assay and
reduces the amount of screening of a possibly much larger protein sequence.
Flowever, if the computer-directed synthesis of Kd motifs does not identify
antigenic peptides within candidate genes, we will consider examining these
sequences using peptide scans. Peptide scan technology is available in our lab,
and entails synthesizing and screening peptides, about 8-10 amino acids in
length, within a given protein. This approach may well turn up an
unconventional Kd binding peptide perhaps in the pre-proinsulin sequence.
The identification of the CD8 T cell autoantigen will also provide a different,
and presumably much more efficient, method of growing the cloned T cell
lines. This could potentially simplify the isolation and propagation of T cell
clones without the continuous need for islets as a source of antigen.

56
B.

Diversification of the T cell autoimmune response
It will be important to determine whether or not all of the cloned T cell

lines derived from young NOD islets (Wong et al., 1996) are responsive to the
same autoantigen. This question can also be applied to the lab's previously
isolated T cell clones (Reich et al., 1989). These were isolated from mice at a
much more advanced stage of the disease process. This would support the
hypothesis that in diabetes, as with other experimental autoimmune diseases,
the initial disease stages involves a T cell response to a very specific antigen
on (3 cells. It has been established that both autoreactive T cells and T-celldependent autoantibodies that characterize organ-specific autoimmune
diseases recognize several distinct molecules, most of which are restricted to
the target cells. This suggests that intermolecular epitope spreading takes
place during autoimmune responses. In addition, the recent observation that
a very limited number of V(3-genes and VDJ-sequences are possibly used by T
cells isolated from single islets, suggests that pathogenic T cell infiltrates
originate from a limited number of T cell clones (Sarukhan et al., 1995).
Thus, a diversity of CD8 T cells, derived from older mice, would be consistent
with the diversification of the T cell response as diabetes progresses.

C.

Islet-specificity of the CD8 T cell autoantigen
Once a candidate cDNA is identified as being antigenic, further

investigation into the islet-specificity of this antigen will be carried out. Since
the peptide antigen is presented in the context of MHC class I, a molecule
which is expressed ubiquitously in other tissues, it will be interesting to
determine whether the identified autoantigen is expressed in and presented
by other tissues. Furthermore, it will be determined whether the autoantigen
is presented on the islets of other non-NOD mice which express the same or
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different MHC class I molecule. In principle this has been demonstrated
where the diabetogenicity of the CD8 clones is preserved when transferred to
H-2Kd expressing CB17.scid mice, but not B6.scid, which express H-2Kb (Wong
et al., 1996).
Interestingly, when several candidate cDNAs were sequenced and
identified, one was identified as the P cell specific molecule, preproinsulin,
whereas two others were identified as preproglucon, synthesized by islet a
cells, and a-amylase, produced by the exocrine pancreas. Although none of
these proteins appear to be the antigen recognized by these cloned CD8 T cells,
their diversity raises the interesting question of whether the CD8 T cells
recognize an antigen expressed only on the islet P cells, or if they can be
triggered by antigen-expressing islet a cells, or even the exocrine pancreas,
before going on to destroy P cells. It is possible that this would take place if
the inciting cell, expressing B7 co-stimulatory molecules, activated reactive T
cells and led to the expression of FasL on the T cell (Alderson et al., 1995;
Russell et al., 1993). When these FasL-expressing activated T cells encounter P
cells which bear the Fas receptor on its surface, P cells could undergo
apoptosis (Chervonsky et al., 1997). On the other hand, it has recently been
demonstrated that class I-restricted CD8 T cells can be stimulated by human
dendritic cells, which efficiently present antigen acquired from self-tissue
(Albert et al., 1998). This suggests that cytotoxic T cells are not restricted to
recognizing antigens that are solely synthesized in the cytoplasm of their
target cells.
Nonetheless, there exists strong evidence that the antigenic targets of
cytotoxic T cells are expressed on the islet P cells themselves. All of the
autoantigens identified to date in IDDM are expressed on islet P cells. In fact
insulin and proinsulin are expressed only by P cells. Furthermore, it has been
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shown that the transfer of diabetogenic T cells into (3-cell-depleted NOD mice
(whose (3 cells have been selectively destroyed) does not allow the survival of
such cells, as demonstrated by their inability to cause diabetes in a secondary
transfer into prediabetic NOD mice bearing functional P cells (Larger et al.,
1995). This suggests that islet P cells bear the target antigens of these
diabetogenic T cells and drive the autoimmune response. Finally, type 1
diabetic patients show decreasing titers of P-cell specific autoantibodies which
eventually disappear following the clinical onset of their disease, when all P
cells are destroyed (Irvine et al., 1977). Similarly, these autoantibodies rapidly
reappear following islet or pancreas transplantation (Sutherland et al., 1984).

5. Antigen-specific immunotherapy
A very important goal once, and if, an autoantigen is elucidated, is to
explore the potential use of the antigen as a treatment modality for disease
prevention.

Autoantigen-based immunotherapy has previously been

attempted by targeting the autoreactive T cells for immune intervention.
One way to block their pathogenic activity is to induce tolerance in the
autoreactive T cells by using autoantigen-derived peptides. This selectively
eliminates the unwanted T cells. Here, it will be determined if the
autoantigenic peptide can be manipulated such that it binds to T cell but does
not induce a response, thus effectively antagonizing the T cell response.
These antagonist peptides could be used in the NOD mouse in vivo to
prevent disease. The autoantigenic peptide will be mutated to generate
variant peptides, which can then be characterized in vitro using agonist
peptides and the cloned cells. T cell hybrids will also be used to test for
antagonizing effects of these peptides. Once antagonist peptides are identified
in vitro, they will then be injected into mice and tested for their in vivo
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ability to inhibit diabetes. Another antigen-specific approach to inhibit the
activity of the diabetogenic T cells is through oral and nasal administration of
antigen or antigenic peptides. Such immunotherapy was carried out using
GAD and insulin, and resulted in the down-regulation of self-reactive T cells,
and in the case of insulin, the production of protective gamma-delta (y5) T
cells (Harrison et al., 1996; Tian et al., 1996; Zhang et al., 1991). Thus, oral
tolerance may prove to be another method by which the CD8 T cell
autoantigen can be used to treat and prevent disease.
Previous studies have shown that the treatment of young mice with
the {3-cell antigen GAD, can tolerize GAD-specific T cells and in turn prevent
diabetes in the NOD mouse (Kaufman et al., 1993; Tisch et al., 1993). This
protection seems to result from the induction of a protective Th2-like
response (Zechel et al., 1997). Intrathymic administration of GAD, as a means
of inducing a central tolerance (by deletion), has been less conclusive, and
some authors have even found peptide administration to exacerbate the
diabetic process rather than delay or suppress it (Cetkovic-Cvrlje et al., 1997).
More recent studies have demonstrated tolerance induction to insulin
(French et al., 1997; Muir et al., 1995; Zhang et al., 1991), and down-regulation
of T cell reactivities to HSP60 protects NOD mice from diabetes (Birk et al.,
1996; Elias and Cohen, 1994). In the case of multiple sclerosis (MS), treatment
with immunodominant peptides of the myelin basic protein (MBP) can
prevent and treat the CD4 T cell-mediated murine model of experimental
autoimmune encephalomyelitis (Smilek et al., 1991; Wraith et al., 1989).
Thus, it appears that peptide-specific immunotherapy, when applied to highly
defined models of autoimmunity, can be effective.
In diseases such as IDDM, or MS, in which the target autoantigen(s) is
not known and a number of autoantigens appear to be involved in the
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disease process, it is less clear how such a peptide-specific approach could be
feasible. At this time there is no consensus as to which antigens in IDDM are
most effective in this process. However, studies do suggest that this form of
immunotherapy may be successful in a clinical setting, where success hinges
on whether the therapy can be used to treat an ongoing autoimmune
response or whether it can be useful only in disease prevention (Tisch and
McDevitt, 1994). Furthermore, there are many questions that remain
unanswered. How many (3-cell autoantigens have not been identified, and do
primary or triggering antigens exist in NOD mice? How are NOD mouse
autoantigens similar to or different from human (3-cell antigens? In the past,
most assays have focused on the antigens recognized by CD4 T cells. It is now
becoming apparent that CD8 T cells play a critical role as initiators of insulitis.
Thus, it is likely that by elucidating the autoantigens recognized by CD8 T
cells, we will be able to address many of these unanswered questions.
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Conclusion
In this thesis we describe the application of the lacZ assay as a means of
identifying the target antigen of a CD8 T cell clone, isolated from young NOD
mice, which transfers rapid-onset diabetes in the absence of CD4 T cells.
Defining the ligands of T cells involved in IDDM is an extremely important
component of understanding the immunological mechanisms underlying
diabetogenesis and autoimmunity in general. CD8 T cells appear to be critical
initiators of diabetes, and it may well be that the antigenic targets of CD8 T
cells play a role in disease induction. However, the antigenic targets of CD8 T
cell have not been identified in type 1 diabetes. Their identification may
provide insight into the existence and nature of a primordial autoantigen in
the pathogenesis of IDDM. Identifying T cell autoantigens has been a difficult
task. Here we make use of an expression cloning strategy which takes
advantage of a highly sensitive single-cell T cell assay. We aim to manipulate
the IcicZ assay in an effort to further increase the sensitivity of the indicator T
cells, and continue to screen the islet cDNA library in smaller pools. This will
help to enable our endeavor to identify the autoantigen of the diabetogenic
CD8 T cell clone, and subsequently explore its potential as a treatment
modality for disease prevention.
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